We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can 2020 Strategy Aid Clorox Despite Soft View & High Costs?
Read MoreHide Full Article
Shares of The Clorox Company (CLX - Free Report) have lost 1.8% in the past three months against the industry’s growth of 8.9%. The stock’s bearish run on the bourses can be attributable to lower-than-expected third-quarter fiscal 2019 results. Elevated commodity costs, adverse currency rates, and increased manufacturing and logistics expenses hurt results to some extent. Following this, management slashed its guidance for fiscal 2019.
The company now projects sales growth of 2-3% compared with the prior guidance of 2-4%. The lowered sales view is mainly due to a milder cold and flu season compared with the prior-year quarter, and increased promotional activity in the Wipes category. The view was also lowered on anticipated softer sales in the Bags and Wraps business, due to widened price gaps as a result of price increase and higher competitive promotions. For fiscal 2019, management anticipates earnings per share of $6.25-$6.35 from continuing operations compared with the prior view of $6.20-$6.40. Notably, earnings projection includes negative impact of nearly 5-7 cents from tariffs, which are hurting certain business segments.
Although earnings estimate for this Zacks Rank #3 (Hold) company have remained stable in the past 60 days, the same for both fiscal 2019 and 2020 moved south by 0.3% and 2% to $6.29 and $6.53, respectively.
These apart, the company’s muted gross margin view for fiscal 2019 is a concern. In fiscal 2019, the company expects gross margin to remain flat, as gains from higher prices are likely to be offset by increased costs and adverse foreign currency exchange rates.
That said, management is looking into every nook and cranny for growth prospects. In this regard, it remains poised on the smooth execution of its 2020 Strategy, which is aimed at improving categories and overall market share. The strategy focuses on achieving certain long-term aspirations like growing net sales by 3-5%, increasing EBIT margin by 25-50 basis points (bps) and generating free cash flow of 10-12% of sales, all on a yearly basis. Clorox’s 2020 Strategy is meant to be achieved through key accelerators like investment in brands, development of e-commerce, technological advancements, enhancement of growth culture, and focus on the 3Ds — desire, decision and delight.
Moreover, the company is making efforts to enhance its digital capabilities. This led to a strong performance in the e-commerce business, which is now a significant revenue contributor. The company is ahead of track and nearing its 2020 target of achieving $500 million from e-commerce sales.
General Mills (GIS - Free Report) has a long-term earnings growth of 7% and a Zacks Rank #2.
Vitamin Shoppe has a positive earnings surprise of 319.6% in the trailing four quarters and a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
Image: Shutterstock
Can 2020 Strategy Aid Clorox Despite Soft View & High Costs?
Shares of The Clorox Company (CLX - Free Report) have lost 1.8% in the past three months against the industry’s growth of 8.9%. The stock’s bearish run on the bourses can be attributable to lower-than-expected third-quarter fiscal 2019 results. Elevated commodity costs, adverse currency rates, and increased manufacturing and logistics expenses hurt results to some extent. Following this, management slashed its guidance for fiscal 2019.
The company now projects sales growth of 2-3% compared with the prior guidance of 2-4%. The lowered sales view is mainly due to a milder cold and flu season compared with the prior-year quarter, and increased promotional activity in the Wipes category. The view was also lowered on anticipated softer sales in the Bags and Wraps business, due to widened price gaps as a result of price increase and higher competitive promotions. For fiscal 2019, management anticipates earnings per share of $6.25-$6.35 from continuing operations compared with the prior view of $6.20-$6.40. Notably, earnings projection includes negative impact of nearly 5-7 cents from tariffs, which are hurting certain business segments.
Although earnings estimate for this Zacks Rank #3 (Hold) company have remained stable in the past 60 days, the same for both fiscal 2019 and 2020 moved south by 0.3% and 2% to $6.29 and $6.53, respectively.
These apart, the company’s muted gross margin view for fiscal 2019 is a concern. In fiscal 2019, the company expects gross margin to remain flat, as gains from higher prices are likely to be offset by increased costs and adverse foreign currency exchange rates.
That said, management is looking into every nook and cranny for growth prospects. In this regard, it remains poised on the smooth execution of its 2020 Strategy, which is aimed at improving categories and overall market share. The strategy focuses on achieving certain long-term aspirations like growing net sales by 3-5%, increasing EBIT margin by 25-50 basis points (bps) and generating free cash flow of 10-12% of sales, all on a yearly basis. Clorox’s 2020 Strategy is meant to be achieved through key accelerators like investment in brands, development of e-commerce, technological advancements, enhancement of growth culture, and focus on the 3Ds — desire, decision and delight.
Moreover, the company is making efforts to enhance its digital capabilities. This led to a strong performance in the e-commerce business, which is now a significant revenue contributor. The company is ahead of track and nearing its 2020 target of achieving $500 million from e-commerce sales.
Looking for Consumer Staples Stocks? Check These
Campbell Soup Company (CPB - Free Report) has a long-term earnings growth of 5% and a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
General Mills (GIS - Free Report) has a long-term earnings growth of 7% and a Zacks Rank #2.
Vitamin Shoppe has a positive earnings surprise of 319.6% in the trailing four quarters and a Zacks Rank #2.
Today's Best Stocks from Zacks
Would you like to see the updated picks from our best market-beating strategies? From 2017 through 2018, while the S&P 500 gained +15.8%, five of our screens returned +38.0%, +61.3%, +61.6%, +68.1%, and +98.3%.
This outperformance has not just been a recent phenomenon. From 2000 – 2018, while the S&P averaged +4.8% per year, our top strategies averaged up to +56.2% per year.
See their latest picks free >>